Loading...
•
Sep 30, 2020
Halozyme Q3 2020 Earnings Report
Reported a strong third quarter driven by royalty revenue growth and partner clinical trial progress.
Key Takeaways
Halozyme Therapeutics, Inc. reported third quarter 2020 financial results with revenue of $65.3 million and EPS of $0.25. The company is raising its full year 2020 financial guidance due to improved outlook for royalties and greater visibility on anticipated milestone revenues.
Revenue for the third quarter was $65.3 million, compared to $46.2 million for the third quarter of 2019.
Net income for the third quarter was $36.2 million, or $0.25 per share, compared to a net loss in the third quarter of 2019 of $25.0 million, or $0.17 per share.
The year-over-year increase was primarily driven by $32.0 million in collaboration revenue from Roche and argenx in the current period.
The company is raising full year 2020 financial guidance and now expects revenues of $250 million to $260 million and earnings per share on a GAAP basis of $0.80 to $0.85.
Revenue by Segment
Forward Guidance
The Company is raising full year 2020 financial guidance and now expects revenues of $250 million to $260 million and earnings per share on a GAAP basis of $0.80 to $0.85.
Positive Outlook
- Revenues of $250 million to $260 million
- Represents growth of 28 to 33% over prior year revenues
- Earnings per share on a GAAP basis of $0.80 to $0.85
- Increased from prior revenue guidance of $230 million to $245 million
- Increased from prior EPS guidance of $0.60 to $0.75
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...